United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - adalimumab - solution for injection - 50mg/1ml

Israel - English - Ministry of Health

megapharm ltd - miltefosine - hard capsule - miltefosine 10 mg - miltefosine - -treatment of visceral leishmaniasis caused by leishmania donovani. -treatment of cutaneous leishmaniasis caused by leishmania brasiliensis complex or leishmania mexicana complex.

Israel - English - Ministry of Health

megapharm ltd - miltefosine - hard capsule - miltefosine 50 mg - miltefosine - -treatment of visceral leishmaniasis caused by leishmania donovani. -treatment of cutaneous leishmaniasis caused by leishmania brasiliensis complex or leishmania mexicana complex.

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - imatinib - film-coated tablet - 100 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib clonmel is indicated in:
paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment.
paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
adult patients with ph+ cml in blast crisis
adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy.
adult patients with relapsed or refractory ph+ all as monotherapy.
adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements.
adult patients with advanced hypereosino

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - imatinib - film-coated tablet - 400 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib clonmel is indicated in:
paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment.
paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
adult patients with ph+ cml in blast crisis
adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy.
adult patients with relapsed or refractory ph+ all as monotherapy.
adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements.
adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr
rearrangement.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - loteprednol etabonate - eye drops - 5mg/1ml